Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 4/20 | 0.44 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.42 |
| ▸ | ADRB3 | P13945 | 6/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | AR | P10275 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | PDE4A | P27815 | 1/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
| ▸ | ESRRA | P11474 | 1/20 | 0.39 |
| ▸ | F2 | P00734 | 1/20 | 0.38 |
| ▸ | F10 | P00742 | 1/20 | 0.38 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.38 |
| ▸ | F7 | P08709 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6479480 | 1.00 | CYP19A1 (0.44) | CYP19A1TRPV1ADRB3NPC1AR | |
| SCHEMBL4817546 | 1.00 | CYP19A1 (0.44) | CYP19A1TRPV1ADRB3NPC1AR | |
| SCHEMBL7605348 | 0.90 | CYP19A1 (0.44) | CYP19A1TRPV1ADRB3NPC1AR | |
| SCHEMBL7605339 | 0.90 | CYP19A1 (0.44) | CYP19A1TRPV1ADRB3NPC1AR | |
| SCHEMBL7109194 | 0.89 | AR (0.43) | CYP19A1TRPV1ADRB3NPC1AR | |
| SCHEMBL7111557 | 0.89 | AR (0.43) | CYP19A1TRPV1ADRB3NPC1AR | |
| SCHEMBL7109191 | 0.89 | AR (0.43) | CYP19A1TRPV1ADRB3NPC1AR | |
| SCHEMBL6986483 | 0.87 | ADRB3 (0.48) | CYP19A1TRPV1ADRB3PDE4APDE4B | |
| SCHEMBL8817465 | 0.86 | CYP19A1 (0.43) | CYP19A1TRPV1ADRB3NPC1AR | |
| SCHEMBL9234212 | 0.84 | CYP19A1 (0.46) | CYP19A1TRPV1ADRB3NPC1AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7217724-B2 | Indole, indazole, and benzazole derivative | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-05-15 | — | — | US | disclosed |
| US-20060063762-A1 | Indole indazole and benzazole derivative | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2006-03-23 | — | — | US | disclosed |
| EP-1514869-A1 | INDOLE, INDAZOLE, AND BENZAZOLE DERIVATIVE | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2005-03-16 | — | — | EP | disclosed |
| US-20050043358-A1 | Aminoalcohol derivatives and their use as beta 3 adrenergic agonists | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2005-02-24 | — | — | US | disclosed |
| US-6569873-B2 | Treating or inhibiting metabolic disorders related to insulin resistance or hyperglycemia, atherosclerosis, gastrointestinal disorders, neurogenetic inflammation, glaucoma, ocular hypertension and frequent urination | WYETH | 2003-05-27 | — | — | US | disclosed |
| EP-0659737-B1 | Catecholamine surrogates useful as beta 3 agonists | BRISTOL MYERS SQUIBB CO (US) | 2003-03-26 | — | — | EP | disclosed |
| US-20030055079-A1 | Azolidines as beta-3 adrenergic receptor agonists | WYETH | 2003-03-20 | — | — | US | disclosed |
| US-6465501-B2 | USEFUL IN TREATING OR INHIBITING METABOLIC DISORDERS RELATED TO INSULIN RESISTANCE OR HYPERGLYCEMIA, ATHEROSCLEROSIS, GASTROINTESTINAL DISORDERS, NEUROGENETIC INFLAMMATION, GLAUCOMA, OCULAR HYPERTENSION AND INCONTINENCE | WYETH | 2002-10-15 | — | — | US | disclosed |
| US-20020143034-A1 | Aminoalcohol derivatives and their use as beta 3 adrenergic agonists | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2002-10-03 | — | — | US | disclosed |
| US-20020032222-A1 | Azolidines as beta-3 adrenergic receptor agonists | AMERICAN HOME PRODUCTS CORPORATION (US) | 2002-03-14 | — | — | US | disclosed |
| EP-0659737-A2 | Catecholamine surrogates useful as B3 agonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-06-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055079-A1 | Azolidines as beta-3 adrenergic receptor agonists | GPR119, ADRB1, ADRB3 | CYP19A1 1029/4885TRPV1 1146/4885ADRB3 3/4885 |
| US-20060063762-A1 | Indole indazole and benzazole derivative | ADRB3, ADRA2C, ADRB2 | CYP19A1 309/4885TRPV1 550/4885ADRB3 1/4885 |
| US-20020143034-A1 | Aminoalcohol derivatives and their use as beta 3 adrenergic agonists | ADRB1, ADRB2, ADRB3 | CYP19A1 2541/4885TRPV1 1235/4885ADRB3 3/4885 |
| US-20020032222-A1 | Azolidines as beta-3 adrenergic receptor agonists | GPR119, ADRB1, ADRB3 | CYP19A1 1029/4885TRPV1 1146/4885ADRB3 3/4885 |
| US-20050043358-A1 | Aminoalcohol derivatives and their use as beta 3 adrenergic agonists | ADRB2, ADRB1, ADRB3 | CYP19A1 2410/4885TRPV1 991/4885ADRB3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.